Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MBRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMoleculin's Annamycin cardiac safety data accepted for ASCO poster presentation
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
medium
Pooled cardiac safety data for lead drug candidate Annamycin accepted for poster presentation at the 2026 ASCO Annual Meeting (May 29-June 2 in Chicago). Cardiac safety is a key concern for oncology drugs.
Item 7.01 verify on EDGAR → -
medium
The abstract features data for Annamycin (also called L-Annamycin or naxtarubicin), the company's lead drug candidate currently in clinical development.
Press Release verify on EDGAR →
Summary
Moleculin Biotech announced that pooled cardiac safety data for its lead oncology drug candidate Annamycin has been accepted for poster presentation at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting. The conference runs May 29 through June 2, 2026 in Chicago.
For a small biotech company, acceptance at ASCO represents external validation that the clinical data meets scientific standards worthy of peer review at a major industry gathering. Retail investors should care because cardiac safety is a critical hurdle for cancer drugs, particularly those in the anthracycline class.
Positive safety data could strengthen Annamycin's competitive profile and de-risk the development program. However, this is a poster presentation of pooled data, not a primary clinical trial readout, so expectations should be calibrated accordingly. Watch for the actual poster content and any company commentary after the May 29 presentation date. If the cardiac safety profile is favorable compared to existing treatments, it could support future partnership discussions or regulatory pathways.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 21, 2026, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as “L-Annamycin” or “naxtarubicin”), has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois.
The company disclosed that pooled cardiac safety data for Annamycin, its lead drug candidate, will be presented at the 2026 ASCO Annual Meeting. This represents a scientific milestone where the company's clinical data has been accepted for presentation at a major oncology conference. The focus on cardiac safety data is particularly relevant for an oncology drug candidate.
Event · Item 9.01 — Financial Statements and Exhibits
Moleculin Biotech filed an 8-K attaching a press release dated May 21, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 Press Releasedated May 21, 2026
The 8-K references a press release dated May 21, 2026 as Exhibit 99.1. The filing body provides no details about the content of the press release, so the nature and materiality of any disclosed event cannot be determined from this 8-K text alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify